Breast Cancer | Specialty

Could the USPSTF Breast Cancer Screening Guidelines Affect Insurance Coverage?

March 13th 2016

Do the USPSTF Breast Cancer Screening Guidelines Suggest That Mammograms Are Not Important?

March 13th 2016

Dr. Borgen Discusses 3D Mammography

March 13th 2016

How Do the USPSTF Breast Cancer Screening Guidelines Affect Women With Dense Breasts?

March 13th 2016

Dr. Borgen's Stance on the USPSTF Guidelines

March 13th 2016

The Updated USPSTF Breast Cancer Screening Guidelines

March 13th 2016

Dr. Tripathy on Ixabepilone in Patients With TNBC

March 13th 2016

Debu Tripathy, MD, chair, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the use of ixabepilone as a treatment for patients with triple-negative breast cancer (TNBC).

Genomic Profiling of DCIS Is Ready for Prime Time

March 13th 2016

There is a subset of low-risk patients with ductal carcinoma in situ for whom surgery alone is optimal and the Oncotype DX DCIS Score is a useful assay for identifying these individuals.

Despite Setbacks, pCR Still Acceptable for Breast Cancer Approvals

March 13th 2016

Pathologic complete response may still have a role in accelerated neoadjuvant approvals for select patients with early stage breast cancer, despite the fact that it remains an unproven surrogate endpoint.

Amy Robach on Factors Impacting Her Breast Cancer Treatment Decision

March 12th 2016

Amy Robach, breast cancer survivor and Good Morning America news anchor, describes her diagnosis of a 2 cm tumor in her right breast that appeared isolated on ultrasound and other subsequent scans.

Alpelisib Combo Promising in PIK3CA-Altered, Heavily Pretreated Breast Cancer

March 12th 2016

The combination of the alpha-specific PI3K inhibitor alpelisib (BYL719) and fulvestrant (Faslodex) demonstrated promising early efficacy and mild toxicity in heavily pretreated postmenopausal women with ER-positive metastatic breast cancer.

Nab-Paclitaxel Outduels Paclitaxel in HR+/HER2- and Triple-Negative MBC

March 12th 2016

Among patients with HR+/HER2- or triple-negative metastatic breast cancer, nab-paclitaxel (Abraxane) improved time to treatment discontinuation, time to next treatment, and had a favorable safety profile compared with paclitaxel.

More Data Needed to Confirm Early Results on Carboplatin in TNBC

March 11th 2016

Carboplatin shows promise in treating metastatic BRCA-mutated triple negative breast cancer.

Dr. Symmans on Moon Shots Program for Patients With TNBC

March 11th 2016

William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.

Dr. Blackwell on Late Recurrences in Patients With Breast Cancer

March 10th 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses using the word "cure" in patients with breast cancer who have not had recurrences of disease.

Clinical Utility of Emerging Molecular Diagnostics in Breast Cancer

March 9th 2016

The past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.

Key Studies Help Chart Course in HER2-Positive Breast Cancer

February 28th 2016

Among the bright spots in the treatment of patients with breast cancer are the successes achieved in the management of HER2-positive disease. And, therapeutic options are continuing to expand, owing to the advent of novel anti-HER2–targeted agents and multitargeted HER2 receptor blockade.

Blackwell on Recent Advances in HER2-Positive Breast Cancer

February 25th 2016

Kimberly L. Blackwell, MD, discusses recent studies examining emerging agents in HER2-positive breast cancer.

Dr. Erika P. Hamilton on ONT-380 for HER2+ Breast Cancer

February 25th 2016

Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator, Sarah Cannon Research Institute, discusses ONT-380, a novel HER2-specific inhibitor. Most oral HER2-inhibitors block not only HER2, but other proteins such as EGFR.

FDA Approves Palbociclib in Pretreated HR+/HER2-Negative Breast Cancer

February 19th 2016

The FDA has approved palbociclib (Ibrance) for use in combination with fulvestrant in pretreated patients with HR-positive, HER2-negative metastatic breast cancer.